Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/106215
DC FieldValueLanguage
dc.contributor.authorAndrés-Benito, Pol-
dc.contributor.authorPovedano, Mònica-
dc.contributor.authorDomínguez, Raúl-
dc.contributor.authorMarco, Carla-
dc.contributor.authorColomina, Maria J.-
dc.contributor.authorLópez-Pérez, Óscar-
dc.contributor.authorSantana, Isabel-
dc.contributor.authorBaldeiras, Inês-
dc.contributor.authorMartínez-Yelámos, Sergio-
dc.contributor.authorZerr, Inga-
dc.contributor.authorLlorens, Franc-
dc.contributor.authorFernández-Irigoyen, Joaquín-
dc.contributor.authorSantamaría, Enrique-
dc.contributor.authorFerrer, Isidro-
dc.date.accessioned2023-03-27T08:13:23Z-
dc.date.available2023-03-27T08:13:23Z-
dc.date.issued2020-11-17-
dc.identifier.issn1422-0067pt
dc.identifier.urihttps://hdl.handle.net/10316/106215-
dc.description.abstractSporadic amyotrophic lateral sclerosis (sALS) is a fatal progressive neurodegenerative disease affecting upper and lower motor neurons. Biomarkers are useful to facilitate the diagnosis and/or prognosis of patients and to reveal possible mechanistic clues about the disease. This study aimed to identify and validate selected putative biomarkers in the cerebrospinal fluid (CSF) of sALS patients at early disease stages compared with age-matched controls and with other neurodegenerative diseases including Alzheimer disease (AD), spinal muscular atrophy type III (SMA), frontotemporal dementia behavioral variant (FTD), and multiple sclerosis (MS). SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for protein quantitation, and ELISA for validation, were used in CSF samples of sALS cases at early stages of the disease. Analysis of mRNA and protein expression was carried out in the anterior horn of the lumbar spinal cord in post-mortem tissue of sALS cases (terminal stage) and controls using RTq-PCR, and Western blotting, and immunohistochemistry, respectively. SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed 51 differentially expressed proteins in the CSF in sALS. Receiver operating characteristic (ROC) curves showed CXCL12 to be the most valuable candidate biomarker. We validated the values of CXCL12 in CSF with ELISA in two different cohorts. Besides sALS, increased CXCL12 levels were found in MS but were not altered in AD, SMA, and FTD. Therefore, increased CXCL12 levels in the CSF can be useful in the diagnoses of MS and sALS in the context of the clinical settings. CXCL12 immunoreactivity was localized in motor neurons in control and sALS, and in a few glial cells in sALS at the terminal stage; CXCR4 was in a subset of oligodendroglial-like cells and axonal ballooning of motor neurons in sALS; and CXCR7 in motor neurons in control and sALS, and reactive astrocytes in the pyramidal tracts in terminal sALS. CXCL12/CXCR4/CXCR7 axis in the spinal cord probably plays a complex role in inflammation, oligodendroglial and astrocyte signaling, and neuronal and axonal preservation in sALS.pt
dc.language.isoengpt
dc.publisherMDPIpt
dc.relationMinistry of Economy and Competitiveness, Institute of Health Carlos III (ISCIII) (co-funded by European RegiSonal Development Fund, ERDF, a way to build Europe): FISPI17/000809 to IF; and FIS (ISCIII) grant PI19/00144 to FLl.pt
dc.relationThe Proteomics Unit of Navarrabiomed is supported by grant PT17/0019/009 to JFI, of the PE I+D+I 2013-2016 funded by ISCIII and FEDERpt
dc.relationSpanish Ministry of Science Innovation and Universities (Ref. PID2019-110356RB-I00)pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectamyotrophic lateral sclerosispt
dc.subjectcerebrospinal fluidpt
dc.subjectproteomicspt
dc.subjectbiomarkerspt
dc.subjectCXCL12pt
dc.subjectCXCR4pt
dc.subjectCXCR7pt
dc.subjectAAASpt
dc.subjectS1006Apt
dc.subject.meshAgedpt
dc.subject.meshAged, 80 and overpt
dc.subject.meshAlzheimer Diseasept
dc.subject.meshAmyotrophic Lateral Sclerosispt
dc.subject.meshBiomarkerspt
dc.subject.meshChemokine CXCL12pt
dc.subject.meshFemalept
dc.subject.meshFrontotemporal Dementiapt
dc.subject.meshHumanspt
dc.subject.meshMalept
dc.subject.meshMiddle Agedpt
dc.subject.meshMotor Neuronspt
dc.subject.meshNeurogliapt
dc.subject.meshReceptors, CXCRpt
dc.subject.meshReceptors, CXCR4pt
dc.titleIncreased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosispt
dc.typearticle-
degois.publication.firstPage8680pt
degois.publication.issue22pt
degois.publication.titleInternational Journal of Molecular Sciencespt
dc.peerreviewedyespt
dc.identifier.doi10.3390/ijms21228680pt
degois.publication.volume21pt
dc.date.embargo2020-11-17*
uc.date.periodoEmbargo0pt
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.orcid0000-0002-8114-9434-
crisitem.author.orcid0000-0002-8106-7308-
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
FMUC Medicina - Artigos em Revistas Internacionais
Show simple item record

SCOPUSTM   
Citations

14
checked on Apr 29, 2024

WEB OF SCIENCETM
Citations

13
checked on May 2, 2024

Page view(s)

59
checked on May 7, 2024

Download(s)

28
checked on May 7, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons